Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

This is more than a legal headline: it hardens the market’s view that the asset is not just delayed, but potentially non-viable at commercially useful doses. For a pre-revenue biotech, that shifts the valuation anchor from peak-sales optionality to liquidation/recovery value, which tends to compress EV long before the court case resolves. The practical overhang is financing — any rerun of the program now comes with higher cash burn, weaker negotiating leverage with partners, and a materially worse cost of capital.

The second-order effect is on the biotech IPO window and on similarly structured small-cap names that have leaned on “clean safety” narratives to justify premium pricing. Even if the lawsuit is backward-looking, investors will demand more evidence around cardiac monitoring, dose-response, and tolerability before underwriting any new obesity/appetite or GI-linked story. That can hit upcoming offerings and secondary issuance terms across the group, especially where catalysts are >6 months out and cash runway is tight.

Contrarian view: the move is likely largely in the stock already, so the lawsuit itself is not the fresh catalyst. What still matters is whether management can credibly restart dosing, whether the FDA imposes any broader hold, and whether the company has enough balance-sheet runway to survive another multi-quarter delay. If no clean re-dosing update lands in the next 1-3 months, the stock remains a time-decay short; if it does, the right-size damage may be less about trial termination and more about a much smaller future market than bulls assumed.